The closing price of Atara Biotherapeutics Inc (NASDAQ: ATRA) was $0.71 for the day, down -0.67% from the previous closing price of $0.71. On the day, 1187012 shares were traded.
Ratios:
Our analysis of ATRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.65 and its Current Ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Touchon Pascal sold 24,844 shares for $0.72 per share. The transaction valued at 17,888 led to the insider holds 1,910,652 shares of the business.
Nguyen AnhCo sold 10,746 shares of ATRA for $7,737 on Mar 04 ’24. The EVP, Chief Sci. & Tech Officer now owns 941,397 shares after completing the transaction at $0.72 per share. On Mar 04 ’24, another insider, Murugan Amar, who serves as the EVP, Chief Legal Officer of the company, sold 10,044 shares for $0.72 each. As a result, the insider received 7,232 and left with 727,521 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.86.
Stock Price History:
Over the past 52 weeks, ATRA has reached a high of $3.08, while it has fallen to a 52-week low of $0.20.
Shares Statistics:
A total of 119.36M shares are outstanding, with a floating share count of 110.12M. Insiders hold about 7.74% of the company’s shares, while institutions hold 60.74% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Atara Biotherapeutics, Inc. analysts. The consensus estimate for the next quarter is $27.64, with high estimates of $17.01 and low estimates of $94.47.
Analysts are recommending an EPS of between $Industrials and $Healthcare for the fiscal current year, implying an average EPS of $Energy.
